191 related articles for article (PubMed ID: 12209762)
1. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
Rodríguez CA; Cruz JJ; Martín T; Gómez A; Olaverri A; Hernández M
Cancer; 2002 Aug; 95(3):670-1; author reply 671. PubMed ID: 12209762
[No Abstract] [Full Text] [Related]
2. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
3. [Tumor markers in breast cancer].
Harada Y; Ohuchi N; Ishida T; Ohnuki K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
5. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer.
Brockmann JG; St Nottberg H; Glodny B; Sprakel B; Senninger N
Anticancer Res; 2000; 20(6D):4899-904. PubMed ID: 11332443
[TBL] [Abstract][Full Text] [Related]
6. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
7. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
Nakata B; Ogawa Y; Ishikawa T; Ikeda K; Kato Y; Nishino H; Hirakawa K
Cancer; 2000 Sep; 89(6):1285-90. PubMed ID: 11002224
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer.
Wu GP; Ba J; Zhao YJ; Wang EH
Acta Cytol; 2007; 51(4):679-80. PubMed ID: 17718156
[No Abstract] [Full Text] [Related]
9. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
10. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
11. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
[No Abstract] [Full Text] [Related]
13. [Serum markers in breast cancer and colorectal cancer (1997)].
Bellet D; Mlika-Cabanne N; Bedenne L; Brun B; Demeaux JL; Legrand JL; Lorimier G; Mignotte H; Ollivier JM; Piperno-Neumann S; Rinaldi Y; Rousset H; Rymer JC; Laversin S
Gynecol Obstet Fertil; 2001 Jan; 29(1):62-3. PubMed ID: 11217195
[No Abstract] [Full Text] [Related]
14. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma.
Uenishi T; Yamazaki O; Yamamoto T; Hirohashi K; Tanaka H; Tanaka S; Hai S; Ono K; Kubo S
J Hepatobiliary Pancreat Surg; 2006; 13(3):239-44. PubMed ID: 16708302
[TBL] [Abstract][Full Text] [Related]
15. Prognostic markers for stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N
Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
[No Abstract] [Full Text] [Related]
16. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
[TBL] [Abstract][Full Text] [Related]
17. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck].
González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A
Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679
[TBL] [Abstract][Full Text] [Related]
18. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
19. [Serum tumor markers for primary lung carcinoma].
Watanabe R; Takiguchi Y; Kuriyama T
Nihon Rinsho; 2000 May; 58(5):1070-3. PubMed ID: 10824551
[TBL] [Abstract][Full Text] [Related]
20. [Carcinoembryonic antigen (CEA) and mucinous-like tumor associated antigen (MAC). Statistic correlation in advanced breast carcinoma].
Sbalzarini G; D'Agostino F; Mercantini F; Girami M; Labadini A; Pandolfi C
Minerva Med; 1991 Dec; 82(12):811-3. PubMed ID: 1780086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]